• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Poll

POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Click here to answer this week's poll.

Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Deucravacitinib
Tapinarof cream
Roflumilast cream
Spesolimab (generalized pustular psoriasis)

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
1 expert in this video
1 expert in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
© 2025 MJH Life Sciences

All rights reserved.